Is nifedipine a calcium (Ca) channel blocker?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Nifedipine as a Calcium Channel Blocker

Yes, nifedipine is definitively a calcium channel blocker, specifically a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. 1

Pharmacological Classification and Mechanism

  • Nifedipine belongs to the dihydropyridine subclass of calcium channel blockers, one of three chemically distinct subclasses (the others being benzothiazepines like diltiazem and phenylalkylamines like verapamil) 2
  • It works by selectively inhibiting calcium ion influx across cell membranes of vascular smooth muscle and cardiac muscle without altering serum calcium concentrations 1
  • Nifedipine binds to voltage-dependent and possibly receptor-operated channels in vascular smooth muscle, resulting in inhibition of calcium influx through these channels 1

Pharmacodynamic Effects

  • As a calcium channel blocker, nifedipine causes peripheral arterial vasodilation, making it effective for treating hypertension and angina 3
  • Among calcium channel blockers, nifedipine produces the most marked peripheral arterial vasodilation compared to other agents in its class 2
  • The reduction in calcium influx by nifedipine causes arterial vasodilation and decreased peripheral vascular resistance, which results in reduced arterial blood pressure 1, 4

Clinical Applications

  • Nifedipine is primarily used for the management of:
    • Hypertension (including hypertensive urgencies) 5, 6
    • Angina pectoris 4
    • Has been used in pulmonary hypertension in titrated doses 2

Important Clinical Considerations

  • Nifedipine or other dihydropyridines should not be used without concomitant beta-blocker therapy in coronary artery disease due to potential increased cardiovascular risk 2
  • Several analyses suggest that short-acting nifedipine might be associated with a dose-dependent detrimental effect on mortality in patients with coronary artery disease 2
  • In acute coronary syndromes, there was a trend toward increased risk of myocardial infarction or recurrent angina with nifedipine compared to placebo in the HINT study 2

Pharmacokinetics

  • Nifedipine is completely absorbed after oral administration 1
  • Extended-release formulations have an elimination half-life of approximately 7 hours compared to 2 hours for immediate-release formulations 1
  • Once-daily dosing of extended-release nifedipine results in decreased fluctuations in plasma concentration compared to multiple daily dosing with immediate-release formulations 1

Unique Properties Among Calcium Channel Blockers

  • Unlike non-dihydropyridine calcium channel blockers (verapamil and diltiazem), nifedipine has minimal direct effects on atrioventricular conduction and heart rate 2, 7
  • Nifedipine may also facilitate neurotransmitter release through a mechanism independent of its calcium channel blocking effects, which may explain some of its side effects 8

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Interaction Between Adalat (Nifedipine) and Fiorinal

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The role of existing and newer calcium channel blockers in the treatment of hypertension.

Journal of clinical hypertension (Greenwich, Conn.), 2004

Research

Pharmacology and mechanisms of action of calcium-channel blockers.

Journal of clinical hypertension, 1986

Research

Nifedipine facilitates neurotransmitter release independently of calcium channels.

Proceedings of the National Academy of Sciences of the United States of America, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.